Bristol-Myers Squibb Continues to Lead the Advancement of Immuno-Oncology

Results for nivolumab and Yervoy® (ipilimumab) as a combination regimen in three tumor types to be presented, including melanoma and the first findings in non-small cell lung cancer and renal cell carcinoma.05/06/2014
Source: Kidney Cancer Association - Category: Cancer & Oncology Source Type: news